-
Start Preamble
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH or Center) is announcing an invitation for participation in its Experiential Learning Program (ELP). The ELP provides a formal training mechanism for regulatory review staff to visit research, clinical, manufacturing, and health care facilities to observe firsthand how medical devices are designed, developed, and utilized. This training is intended to provide CDRH staff with an opportunity to observe the device development life cycle and provide a better understanding of the medical devices they review and the challenges faced throughout development, testing, manufacturing, and clinical use. The purpose of this document is to invite medical device industry, academia, and health care facilities to participate in this formal training program for FDA's medical device review staff, or to contact CDRH for more information regarding the program.
DATES:
Submit either an electronic or written request for participation in this program by June 2, 2014. The request should include a description of your facility relative to product areas regulated by CDRH. Please include the Area of Interest (see table 1 or 2) that the site visit will demonstrate to CDRH staff, a contact person, site visit location, length of site visit, proposed dates, and maximum number of CDRH staff that can be accommodated during a site visit. Submitted proposals without this information will not be considered. In addition, please include an agenda outlining the proposed training for the site visit. A sample request and agenda are available on the ELP Web site: http://www.fda.gov/downloads/ScienceResearch/ScienceCareerOpportunities/UCM392988.pdf Start Printed Page 24730and http://www.fda.gov/scienceresearch/sciencecareeropportunities/ucm380676.htm.
ADDRESSES:
Submit either electronic requests to http://www.regulations.gov or written requests to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville MD 20852. Identify comments with the docket number found in brackets in the heading of this document.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Latonya Powell, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 4448, Silver Spring, MD 20993-0002, 301-796-6965, FAX: 301-827-3079, Latonya.powell@fda.hhs.gov.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
I. Background
CDRH launched the ELP Pilot in 2012 and fully implemented the program (78 FR 19711, April 2, 2013) in 2013. The Center is responsible for ensuring the safety and effectiveness of medical devices marketed in the United States. Furthermore, CDRH assures that patients and providers have timely and continued access to high-quality, safe, and effective medical devices and safe radiation-emitting products. In support of this mission, the Center launched various training and development initiatives to enhance performance of its staff involved in regulatory review and in the premarket review process. CDRH is committed to advancing regulatory science; providing industry with predictable, consistent, transparent, and efficient regulatory pathways; and helping to ensure consumer confidence in medical devices marketed in the United States and throughout the world. This program is a collaborative effort to enhance communication and facilitate the premarket review process. Furthermore, CDRH is committed to understanding current industry practices, innovative technologies, and regulatory impacts and needs.
These formal training visits are not a mechanism for FDA to inspect, assess, judge, or perform a regulatory function (i.e., compliance inspection), but rather, are an opportunity to provide the CDRH review staff a better understanding of the products they review. Through this notice, CDRH is formally requesting participation from companies; academia; and clinical facilities, including those that have previously participated in the ELP; other FDA site visit programs; and new interested parties.
II. ELP
A. Experiential Learning Program
In this program, groups of CDRH staff will observe operations of medical device establishments, including research, manufacturing, academia, and health care facilities. The areas of focus and specific areas of interest for visits may include the following:
Start Printed Page 24731Table 1—Areas of Interest—Medical Devices/Technology
Focus area Specific areas of interest Advanced simulation testing of mechanical ventilators Performance testing of closed loop controlled ventilators using advanced physiologic simulation and computational modeling of the system (patient, ventilator, and sensor). Assisted reproductive technology (ART) clinic setting Structure and organization of an ART clinic; understanding the necessary specifications for ART devices (incubators, microscopes, media, micromanipulation, assisted reproduction lasers, and lab ware); cleaning and disinfection of reprocessed instruments in the ART clinic; aseptic techniques used in ART clinic. Clinical use of orthopedic bone void filler devices Observation of surgical procedures (posterolateral spine fusion, foot, ankle) utilizing bone void fillers. Clinical use of physical medicine devices Rehabilitation hospitals and programs; devices for treatment of pain (transcutaneous electrical nerve stimulator, diathermy), devices for muscle rehabilitation (powered muscle stimulators), devices intended to help restore function to patients (prosthetic limbs, functional electrical stimulators, orthoses). Design and development of ablation devices, including electrosurgical units and accessories, electrosurgical/ultrasonic devices, microwave ablation devices Tumor ablation devices. Electrophysiology (EP) catheters for diagnostic (mapping) and therapeutic (ablation) indications Observe manufacturing and testing of EP devices, with inclusion of design verification and returned product testing, as available. Emerging manufacturing methods for orthopedic devices 3D printing, rapid manufacturing. Endosseous implants Computer Aided Design/Computer Aided Manufacturers produced elements, titanium bases, and various software programs utilized for forming abutments. Hemodialysis devices used in the home environment Home hemodialysis training program, hemodialysis machines, “wetness” detectors, hemodialysis blood access devices, water treatment. Interface between the brain thought processes and the movement of medical devices to assist mobility Brain-computer interface manufacturer or laboratory. Intraocular lenses (IOLs) and injectors Development and manufacture of IOLs and injectors. Manufacturing of polymeric sealants Vascular surgical sealants. Refractive lasers Manufacturing; preclinical testing; femtosecond lasers. Robotic surgery Manufacturing of robotic surgical devices. Table 2—Areas of Interest—In Vitro Diagnostic and Radiological Devices/Technology
Focus area Specific areas of interest Artificial pancreas related devices Manufacturing of continuous glucose monitoring devices and insulin pumps. Manufacturing of different types of human antibodies for the use of immunoassays Manufacturing of antibodies (monoclonal and polyclonal) for immunoassay tests. Coagulation point of care and home use devices Coagulation devices for point of care and home use (COUMADIN self-monitoring) utilizing whole blood and/or citrated plasma. Immunohistochemistry for the diagnostic evaluation for cancer Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Systems capable of running multiple analytes composed of a specimen collection and processing unit at satellite locations and data transmittal to a central location for analysis and quality control oversight Systems maintaining quality oversight of data generated at a distant location and transmitted digitally to another location for analysis. Antimicrobial resistance detection and characterization Observation and hands-on experience with reference methods and assays for phenotypic and non-phenotypic-based methods for determining antimicrobial resistance. Diagnostic x-ray imaging devices Site visits to user facilities. Next generation sequencing/single-nucleotide polymorphism (SNP) arrays and clinical genomics Next generation sequencing and/or SNP array devices in the clinical laboratory setting for molecular diagnostics used. B. Site Selection
CDRH will be responsible for all CDRH staff travel expenses associated with the site visits. CDRH cannot provide funds to support the proposed training provided by the applicants to this program. Selection of potential facilities will be based on CDRH's priorities for staff training and resources available to fund this program. In addition to logistical and other resource factors, all sites must have a successful compliance record with FDA or another Agency with which FDA has a memorandum of understanding. If a site visit involves a visit to a separate physical location of another firm under contract to the applicant, that firm must agree to participate in the program and must also have a satisfactory compliance history.
III. Request for Participation
Identify requests for participation with the docket number found in the brackets in the heading of this document. Received requests may be seen in the Division of Dockets Management (see ADDRESSES) between 9 a.m. and 4 p.m., Monday through Friday.
Start SignatureDated: April 25, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-09916 Filed 4-30-14; 8:45 am]
BILLING CODE 4160-01-P
Document Information
- Published:
- 05/01/2014
- Department:
- Food and Drug Administration
- Entry Type:
- Notice
- Action:
- Notice.
- Document Number:
- 2014-09916
- Dates:
- Submit either an electronic or written request for participation in this program by June 2, 2014. The request should include a description of your facility relative to product areas regulated by CDRH. Please include the Area of Interest (see table 1 or 2) that the site visit will demonstrate to CDRH staff, a contact person, site visit location, length of site visit, proposed dates, and maximum number of CDRH staff that can be accommodated during a site visit. Submitted proposals without this ...
- Pages:
- 24729-24731 (3 pages)
- Docket Numbers:
- Docket No. FDA-2013-N-0338
- PDF File:
- 2014-09916.pdf